Continuous subcutaneous infusion of foslevodopa/foscarbidopa was safe and improved motor complications in patients with advanced Parkinson’s disease, according to data presented at the European Academy of Neurology Congress 2022. “ABBV-951 (foslevodopa/foscarbidopa) is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion being investigated for the